Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 140Breast 12Gynecologic 4Gastrointestinal 4Tumor-Agnostic 2Lymphoid 2Thoracic 1Plasma cell 1Other solid neoplasm 1Other hematologic neoplasm 1Myeloid 1Head & Neck 1Dermatologic 1Classical hematology 1

Conditions

Salivary Cancer 1

Interventions

Cisplatin 416Radiotherapy 240Radiotherapy, Intensity-Modulated 178Cetuximab 177Docetaxel 166pembrolizumab 148Carboplatin 121Fluorouracil 113Paclitaxel 90Nivolumab 82Gemcitabine 82Radiation 72Surveys and Questionnaires 71Drug Therapy 70toripalimab 68Surgical Procedures, Operative 64Magnetic Resonance Spectroscopy 63Capecitabine 50Blood Specimen Collection 50Chemoradiotherapy 46Biopsy 44camrelizumab 41durvalumab 40Radiosurgery 40Standard of Care 38Erlotinib Hydrochloride 34nimotuzumab 32130-nm albumin-bound paclitaxel 32tislelizumab 31apatinib 30

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × enzalutamide × Head & Neck × Clear all
NCT02749903 2026-02-11

Enzalutamide for Patients With Androgen Receptor Positive Salivary Cancers

Alliance for Clinical Trials in Oncology

Phase 2 Active not recruiting
46 enrolled 11 charts
Head & Neck

Salivary Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡